Skip to main content
. Author manuscript; available in PMC: 2020 Aug 15.
Published in final edited form as: Clin Cancer Res. 2019 Sep 26;26(4):804–811. doi: 10.1158/1078-0432.CCR-19-1223

Table 2.

Clinical outcomes by response, PFS, PFS4, OS

Arm Response Progression-Free Survival (median) Progression Free at 2 Months Progression Free at 4 Months Overall Survival
1 0/31* 60 days 41.9% 32.3% 6.4 months
2 0/15 59 days 46.7% 26.7% 7.3 months
*

One unconfirmed response was observed in arm 1 with cabozantinib